Resolution of Inflammation: A Novel Therapeutic Paradigm for Rheumatoid Arthritis and Its Comorbidities. (PubMed, Pharmacol Res) - Sep 30, 2026 - "Resolution pharmacology addresses this question by targeting endogenous pro-resolving pathways involving specialized pro-resolving mediators (SPMs), annexin A1 (AnxA1), melanocortin receptors, the formyl peptide receptor 2 (FPR2/ALX), and related signalling networks. Thus, resolution pharmacology should currently be considered a promising translational framework requiring future clinical validation rather than an established therapeutic paradigm for RA and its comorbidities. CHEMICAL COMPOUNDS IN THIS ARTICLE: Lipoxin A4; Resolvin D1; Resolvin D2; Resolvin D5; Maresin 1; Resomelagon (AP1189); BMS-986235."
Journal • Review • Cardiovascular • Immunology • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology
|
|
Ashton Juin Kai Ng; Brian Basto Franco; Hong Yong Peh; Jianmin Chen; Roshanak Fekri Yazdi; Sze Ian Tan; Weifeng Bu
|